What If You Walk Away Today And They Get Acquired Tomorrow?
This is it.
Not the beginning, not a teaser. Not “early access.”
This is the final few hours to invest in Future Cardia.
If you’ve been following the story, if you’ve read even one of the past articles then you already know the deal:
- A tiny heart monitor that sits quietly under the skin, tracking life-threatening events 24/7
- Already implanted in 39 patients
- Over 60,000 hours of real-world heart data collected
- Tested in top U.S. clinics
- Backed by Stanford StartX, J&J’s JLABS, and investors with billion-dollar exits
- FDA submission planned for end of 2025
- Addressing a $65B+ cardiac monitoring market
You’ve seen the traction, you know the mission. You’ve had time.
So here’s the real question: What if you walk away today, then watch them get acquired next month?
You Think That’s Not How This Happens?
Let’s look at the facts:
- CardioMEMS: acquired pre-FDA for $500 million
- AbioMed: acquired for $16 billion
- Jae Bang, Future Cardia’s founder? He worked with companies backed by the same investors. He walked away from VC control to build something real, with everyday people behind it.
And now, the same people who said no to their first deal will be kicking themselves when the press release hits.
You’re not just investing in a company, you’re investing in a moment. And this moment is closing.
You Don’t Need to Be an Expert, You Just Need to Decide
You don’t need to understand the FDA process, you don’t need to read battery specs or memorize arrhythmia types.
All you need to know is this:
- The problem is huge
- The solution is working
- The round closes today, June 18
- You can invest with $348
And after today? You’re either part of the story… Or you’re the person who watched it happen from the outside.
If you’ve been waiting, this is your line in the sand. One day too late is still too late.
So ask yourself: What if this time you don’t miss it?
*This product is not yet available for purchase and requires review and clearance before being marketed or sold. This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.